Alkermes plc (ALKS) Presents at Evercore eighth Annual Healthcare Convention Transcript

Umer Raffat
Evercore ISI Institutional Equities, Analysis Division

Thanks for becoming a member of us. Richard, tremendous excited to have you ever. I am going to allow you to kick issues off. There’s rather a lot occurring. So I am going to allow you to begin, and I can prioritize accordingly.

Richard F. Pops
Chairman & CEO

Initially, good to see you. Thanks for having us again, over. I used to be simply writing the memo to my Board for our final Board assembly within the yr, summarizing only a transient spotlight of the yr. Some of the consequential years within the historical past of the corporate, I believe. And I believe it would change into a transformational yr, and firms say that on a regular basis, however we actually remodeled the corporate this yr. Final yr right now, we did not have NT1 information, we did not have NT2 information. We hadn’t made the deal to amass Avadel. We now have a really sturdy sense that we’re transferring aggressively into the hypersomnolence market with the potential to actually be a significant pressure in that. That is a very new industrial area for us after a few years. So this — the place we stand proper now could be that we’re truly actually happy with the important thing milestones of the yr. Our industrial portfolio carried out fantastically this yr. NT1 information have been optimistic, NT2 information have been optimistic. IH examine is underway and enrolling properly. The entire panorama of the orexin receptor agonist class, I believe, is coming into focus. And I believe that we discover ourselves rather well positioned in that setting. So I am going to allow you to take it from there.